The 22nd Longevity Prize of the Fondation IPSEN is Awarded to Andrzej Bartke
The Fondation IPSEN Longevity Prize was created in 1996 to recognize the global importance of the continuing increase in human life expectancy. The 2017 prize will be given, today, during the 21st International Association of Gerontology and Geriatrics (IAGG) World Congress of Gerontology and Geriatrics, in San Francisco (2-3.30 pm). The international jury chaired by Professor Thomas Kirkwood (Newcastle University, UK and Copenhagen University, Denmark), has unanimously decided to award the prize to Andrzej Bartke for his pioneering analysis of the molecular and hormonal mechanisms that can extend mammalian longevity in mice.
The Fondation IPSEN Longevity Prize was created in 1996 to recognise the global importance of the continuing increase in human life expectancy. This remarkable increase has implications for a very wide range of scientific disciplines as well as for the organisation of society in all of its aspects.
“The Fondation IPSEN is justifiably proud to have created an award that recognises the intrinsic scientific interest and importance of the topic. Over more than twenty years, the distinguished list of laureates of the Longevity Prize highlights the complementary ways in which the relevant disciplines are making their contributions”, says Thomas Kirkwood, President of the jury (Newcastle University, UK and Copenhagen University, Denmark).
In 2017, the recipient of the Longevity Prize is Dr. Andrzej Bartke (Southern Illinois University School of Medicine, Springfield, USA) for his pioneering analysis of the molecular and hormonal mechanisms that can extend mammalian longevity in Ames dwarf mice. These studies firmly establish neuroendocrine factors as key contributors to the aging processes that affect lifespan.
During this event, Dr. Bartke will present a lecture entitled “Growth and aging; the hidden costs of stature”. Elimination of growth hormone (GH) actions by mutations or targeted gene deletion produces a remarkable extension of longevity in both sexes of laboratory mice. Long-lived GH-deficient and GH-resistant animals are characterized by small body size, delayed puberty, reduced fecundity and a striking delay in multiple symptoms of aging, including the decline of gonadal function. These findings lead to a somewhat counterintuitive conclusion that the normal actions of GH incur significant costs in terms of the impact on aging and longevity. Studies in genetically normal (“wild type”) mice, domestic dogs and various human populations indicate that GH signaling is indeed negatively associated with life expectancy across mammalian species. The evolutionary history of the genetic variation underpinning the trade-offs between growth, maturation, reproductive functions, stress resistance, age-related disease and longevity is difficult to decipher. However, persistence of a wide range of the corresponding phenotypes may benefit survival of populations under challenging environmental conditions.
Andrzej Bartke is Professor of Internal Medicine at Southern Illinois University (SIU) School of Medicine in Springfield, Illinois, USA. The focus of his research is on the genetic and hormonal control of aging in mammals. Current work is aimed at identifying mechanisms that link reduced growth hormone action with delayed aging and extended longevity. For this work, he is using mutant mice that live longer than normal mice and show various symptoms of delayed aging, including retention of cognitive function and protection from age-related disease.
The Longevity Prize
Created in 1996, this Prize of the Fondation IPSEN has been awarded every year to renowned specialists in Longevity:
Caleb E. Finch (University of Southern California, Los Angeles, USA), Vaïno Kannisto (Odense University, Denmark) , Roy L. Walford (formerly University of California Los Angeles, USA), John E. Morley (St. Louis University, USA), Paul B. and Margret M. Baltes (formerly Free University of Berlin, Germany), Justin D. Congdon (University of Georgia, Aiken, USA), George M. Martin (University of Washington, Seattle, USA), James W. Vaupel (Max-Planck Institute for Demographic Research, Rostock, Germany), Linda Partridge (University College London, UK), Sir Michael Marmot (University College London, UK), Cynthia Kenyon (University of California, San Francisco, USA), David J.P. Barker (University of Southampton, UK), Gerald McClearn (Pennsylvania State University, University Park, USA), Jacques Vallin (French National Institute of Demography, Paris, France), Judith Campisi (Buck Institute for Age Research, Novato, USA), Thomas Kirkwood (Newcastle University, Newcastle upon Tyne, UK), Linda Fried (Columbia University, New York, USA), Gary Ruvkun (Harvard Medical School - CCIB, Boston, US), Luigi Ferrucci (National Institute on Aging, NIH, Baltimore, USA), Steven N. Austad (University of Alabama at Birmingham, USA) and Kaare Christensen (Odense University, Denmark).
Members of the jury
Thomas Kirkwood, President (Newcastle University, UK Copenhagen University, Denmark), Judith Campisi (Buck Institute for Research on Aging, Novato, USA), Eileen Crimmins (University of Southern California, Los Angeles, USA) , Caleb Finch (University of Southern California, Los Angeles, USA), Bernard Jeune* (University of Southern Denmark, Odense, Denmark), George Martin* (University of Washington, Seattle, USA), Yasuyuki Gondo (Osaka University, Japan), Jean-Marie Robine (INSERM, Démographie et Santé, Montpellier, France), Bruno Vellas (University of Toulouse, France), Marja Jylhä (University of Tampere, Finland), Steven N. Austad (University of Alabama at Birmingham, USA), Luigi Ferrucci (National Institute on Aging, Baltimore, USA) and a Fondation IPSEN representative.
(* Former Jury Members).
The Fondation IPSEN
Established in 1983 under the aegis of the Fondation de France, the ambition of the Fondation IPSEN is to initiate a reflection about the major scientific issues of the forthcoming years. The long-standing mission of the Fondation IPSEN is to contribute to the development and dissemination of scientific knowledge by fostering interaction between scientists and clinicians. It has developed an important international network of scientific experts who meet regularly at meetings known as Colloques Médecine et Recherche, dedicated to three main topics: neurosciences, endocrinology and cancer science. Moreover the Fondation IPSEN has started several series of meetings in partnership with the Salk Institute, the Karolinska Institute as well as with the science journals Cell and Science. The Fondation IPSEN produced several hundred publications and more than 250 scientists have been awarded prizes and grants.
Yannick TANGUY, +33 (0)6 81187860
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Edgewater Networks Announces Event Sponsorship of BroadSoft Connections 201721.10.2017 00:00 | Tiedote
Edgewater Networks, Inc., the industry leader in Network Edge Orchestration, announced today that it is an event sponsor of the BroadSoft Connections 2017 user conference, which takes place October 22-25 at the JW Marriott Phoenix Desert Ridge Resort & Spa in Phoenix, AZ. During the event, Edgewater Networks will feature demonstrations of the latest end-to-end network interoperability capabilities, including Zero Touch Provisioning, UC Analytics from the core to the endpoint, SD-WAN optimized for BroadSoft, and much more. Continuing a long-standing partnership with BroadSoft, Edgewater Networks has completed another level of BroadCloud certification, this time for local survivability which is critical for business continuity for SMB and Enterprise customers. BroadSoft’s PacketSmart is available on all EdgeMarc Intelligent Edges. All elements of the Network Edge Orchestration are
More than 70 Companies to Showcase Top Tech at CES Unveiled Paris20.10.2017 18:08 | Tiedote
The Consumer Technology Association (CTA) today announced that more than 70 exhibitors will showcase their latest innovations at the now sold-out fifth annual CES Unveiled Paris The event will focus on the Internet of Things (IoT), connectivity and smart cities, and draw more than 600 attendees. CES Unveiled Paris will run from 2-7:30 PM on Tuesday, October 24, 2017 at the Palais Brongniart. Regional technology companies, top-tier media outlets, buyers and key industry influencers will come together at CES Unveiled Paris to get a direct look at the latest industry developments. The day kicks off with a CES news conference and CTA market trends presentation. Conference programming is followed by a tabletop exhibition & networking reception. Curated exhibitors will be there to showcase top tech from robotics and audio to smart home and augmented and virtual reality. Notable
Westinghouse Receives Regulatory Approval for Analysis Methodologies20.10.2017 15:15 | Tiedote
Westinghouse Electric Company today announced that it has received approval from the U.S. Nuclear Regulatory Commission (NRC) for two new important analysis methodologies that will be used to upgrade Westinghouse- and Combustion Engineering-based nuclear steam supply system (NSSS) safety analyses. The approvals granted are for the new FULL SPECTRUMTM Loss of Coolant Accident (FSLOCATM) methodology and the Performance Analysis and Design Model software code update, PAD5. FSLOCA is capable of improved modeling of the transient response in a pressurized water reactor to the full spectrum of LOCA break sizes that could occur, and PAD5 is the next generation of the Westinghouse fuel rod design performance code. “These codes were developed to work in concert with each other to maximize analytical margin for nuclear utilities,” said Michele DeWitt, senior vice preside
Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread®20.10.2017 15:03 | Tiedote
Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from Phase 2 and Phase 3 studies of its approved medicines for chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection, adding to the body of evidence supporting Gilead’s viral hepatitis therapies in diverse patient populations. These and other data from more than 25 abstracts will be presented this week at The Liver Meeting® 2017, which begins today in Washington, D.C. Positive results from studies of Harvoni® (ledipasvir 90mg/sofosbuvir 400mg) in HCV-infected patients with severe renal impairment, Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) in HCV-infected liver transplant recipients and Vosevi® (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg) in NS5A-inhibitor experienced HCV-infected patients will be presented during poster sessions on October 21 and October 22. In addition, updated results f
Schlumberger Announces Third-Quarter 2017 Results20.10.2017 14:00 | Tiedote
Schlumberger Limited (NYSE:SLB) today reported results for the third quarter of 2017. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2017 Jun. 30, 2017 Sept. 30, 2016 Sequential Year-on-year
SP3H Announces That It Has Obtained a €1.2 Million European Union Grant for Its Intelligent and Clean Vehicle (VIP) Project20.10.2017 13:47 | Tiedote
SP3H is proud to announce joining the very select circle of the 10 French winners of the H2020 SME Instrument Phase 2 program since 2014. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171020005325/en/ Last summer VIP received the very prestigious SME instrument phase 2 H2020 label in the "transport & smart cities mobility" category. With an overall budget of € 1.7 million, VIP is subsidized by the European Union at a rate of 70% or €1.2 million. The framework contract was officially signed early October. VIP is the pre-industrialization program for Fuelbox sensors, the world's first miniaturized scanner capable of analyzing the quality of fuels on board vehicles. The heart of the program remains closely linked to the reduction of CO2 and pollutant emissions from vehicle
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme